A Quick and Sensitive LC-MS/MS Method for Simultaneous Quantification of Sofosbuvir Metabolite (GS-331007) in Human Plasma: Application to Hepatitis C Infected Patients with End-Stage Renal Disease

Overview

Journal Middle East J Dig Dis

Specialty Gastroenterology

Date 2024 Aug 12

PMID 39131108

Authors

Sara Majd Jabbari

Maryam Dibaie

Khadije Maajani

Shahin Merat

Sadaf Ghajarieh Sepanlou

Mohammad-Reza Rouini

Affiliations

Soon will be listed here.

Abstract

Background: Sofosbuvir (SOF) is a revolutionary treatment for patients with hepatitis C virus (HCV). However, its efficacy and safety among patients with end-stage renal disease (ESRD) remains controversial. In this study, we examined the levels of SOF metabolite (GS-331007) (SOF-007) in human plasma of patients infected with HCV having ESRD using an optimized liquid chromatography-mass spectrometry (LC-MS) analytical method.

Methods: In this case-control study, 10 clinically confirmed cases and five controls were enrolled. SOF-007 was extracted from plasma using methanol precipitation. The limit of detection (LOD) for the drug and its metabolite were 0.85 and 2.3, respectively. Such a wide range of quantification in a period of separation time shorter than 3.0 minutes (run time) allowed monitoring of the plasma concentration of analytes up to 4 hours (pre-dialysis and post-dialysis) for 12 weeks in non-cirrhotic patients with HCV infection undergoing dialysis.

Results: SOF-007 in the plasma of HCV patients with healthy kidneys showed no cumulative effect. An analysis comparing patients with ESRD and healthy participants showed that their behaviour was similar, followed by dialysis with a relatively small cumulative effect.

Conclusion: The plasma concentrations of SOF-007 decreased significantly after the 4-hour period of dialysis compared with the plasma concentrations hemodialysis of pre-dialysis in HCV patients with ESRD.

References

Zimmer D . New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanalysis. 2013; 6(1):13-9. DOI: 10.4155/bio.13.298. View

Alberti A, Piovesan S . The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications. Dig Liver Dis. 2014; 46 Suppl 5:S174-8. DOI: 10.1016/j.dld.2014.09.028. View

Rezk M, Basalious E, Karim I . Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. J Pharm Biomed Anal. 2015; 114:97-104. DOI: 10.1016/j.jpba.2015.05.006. View

Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, Ammassari A . UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1073:183-190. DOI: 10.1016/j.jchromb.2017.12.018. View

Eldrup A, Prhavc M, Brooks J, Bhat B, Prakash T, Song Q . Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem. 2004; 47(21):5284-97. DOI: 10.1021/jm040068f. View

Cox-North P, Hawkins K, Rossiter S, Hawley M, Bhattacharya R, Landis C . Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun. 2018; 1(3):248-255. PMC: 5721450. DOI: 10.1002/hep4.1035. View

Poustchi H, Majd Jabbari S, Merat S, Sharifi A, Shayesteh A, Shayesteh E . The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. J Gastroenterol Hepatol. 2020; 35(9):1590-1594. DOI: 10.1111/jgh.14994. View

Berden F, Kievit W, Baak L, Bakker C, Beuers U, Boucher C . Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med. 2014; 72(8):388-400. View

Cholongitas E, Papatheodoridis G . Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 2014; 27(4):331-337. PMC: 4188929. View

10.

Stehman-Breen C, Emerson S, Gretch D, Johnson R . Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998; 32(4):629-34. DOI: 10.1016/s0272-6386(98)70027-7. View

11.

Majd Jabbari S, Maajani K, Merat S, Poustchi H, Sepanlou S . An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLoS One. 2021; 16(2):e0246594. PMC: 7875415. DOI: 10.1371/journal.pone.0246594. View

12.

Soderholm J, Millbourn C, Busch K, Kovamees J, Schvarcz R, Lindahl K . Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol. 2017; 68(5):904-911. DOI: 10.1016/j.jhep.2017.12.003. View

13.

Sofia M, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S . Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010; 53(19):7202-18. DOI: 10.1021/jm100863x. View

14.

Gaur N, Malhotra V, Agrawal D, Singh S, Beniwal P, Sharma S . Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. J Clin Exp Hepatol. 2020; 10(3):189-193. PMC: 7212294. DOI: 10.1016/j.jceh.2019.10.004. View

15.

Cha A, Budovich A . Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P T. 2014; 39(5):345-52. PMC: 4029125. View